Repositorio Dspace

Angiogenic role of miR-20a in breast cancer

Mostrar el registro sencillo del ítem

dc.contributor.author Luengo-Gil, Ginés
dc.contributor.author González-Billalabeitia, Enrique
dc.contributor.author Alejo-Pérez-Henarejos, Sergio
dc.contributor.author Navarro-Manzano, Esther
dc.contributor.author Chaves-Benito, Asunción
dc.contributor.author García-Martínez, Elena
dc.contributor.author García-Garre, Elisa
dc.contributor.author Vicente, Vicente
dc.contributor.author Ayala-de-la-Peña, Francisco
dc.date.accessioned 2026-01-22T07:32:21Z
dc.date.available 2026-01-22T07:32:21Z
dc.date.issued 2018-04-04
dc.identifier.citation Luengo-Gil G, Gonzalez-Billalabeitia E, Perez-Henarejos SA, Navarro Manzano E, Chaves-Benito A, Garcia-Martinez E, et al. Angiogenic role of miR-20a in breast cancer. Ahmad A, editor. PLoS ONE. 4 de abril de 2018;13(4):e0194638.
dc.identifier.issn 1932-6203
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/23930
dc.description.abstract BACKGROUND: Angiogenesis is a key process for tumor progression and a target for treatment. However, the regulation of breast cancer angiogenesis and its relevance for clinical resistance to antiangiogenic drugs is still incompletely understood. Recent developments on the contribution of microRNA to tumor angiogenesis and on the oncogenic effects of miR-17-92, a miRNA cluster, point to their potential role on breast cancer angiogenesis. The aim of this work was to establish the contribution of miR-20a, a member of miR-17-92 cluster, to tumor angiogenesis in patients with invasive breast carcinoma. METHODS: Tube-formation in vitro assays with conditioned medium from MCF7 and MDA-MB-231 breast cancer cell lines were performed after transfection with miR-20a and anti-miR20a. For clinical validation of the experimental findings, we performed a retrospective analysis of a series of consecutive breast cancer patients (n = 108) treated with neoadjuvant chemotherapy and with a full characterization of their vessel pattern and expression of angiogenic markers in pre-treatment biopsies. Expression of members of the cluster miR-17-92 and of angiogenic markers was determined by RT-qPCR after RNA purification from FFPE samples. RESULTS: In vitro angiogenesis assays with endothelial cells and conditioned media from breast cancer cell lines showed that transfection with anti-miR20a in MDA-MB-231 significantly decreased mean mesh size and total mesh area, while transfection with miR-20a in MCF7 cells increased mean mesh size. MiR-20a angiogenic effects were abrogated by treatment with aflibercept, a VEGF trap. These results were supported by clinical data showing that mir-20a expression was higher in tumors with no estrogen receptor or with more extensive nodal involvement (cN2-3). A higher miR-20a expression was associated with higher mean vessel size (p = 0.015) and with an angiogenic pattern consisting in larger vessels, higher VEGFA expression and presence of glomeruloid microvascular proliferations (p<0.001). This association was independent of tumor subtype and VEGFA expression. CONCLUSIONS: Transfection of breast cancer cells with miR-20a induces vascular changes in endothelial tube-formation assays. Expression of miR-20a in breast invasive carcinomas is associated with a distinctive angiogenic pattern consisting in large vessels, anomalous glomeruloid microvascular proliferations and high VEGFA expression. Our results suggest a role for miR-20a in the regulation of breast cancer angiogenesis, and raise the possibility of its use as an angiogenic biomarker.
dc.language.iso eng
dc.publisher PUBLIC LIBRARY SCIENCE
dc.rights Atribución/Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es *
dc.subject.mesh Angiogenesis Inhibitors/therapeutic use
dc.subject.mesh Antagomirs/metabolism
dc.subject.mesh Biomarkers, Tumor/genetics/metabolism
dc.subject.mesh Breast Neoplasms/blood supply/drug therapy/genetics/pathology
dc.subject.mesh Cell Line, Tumor
dc.subject.mesh Databases, Factual
dc.subject.mesh Female
dc.subject.mesh Humans
dc.subject.mesh MCF-7 Cells
dc.subject.mesh MicroRNAs/antagonists & inhibitors/genetics/metabolism
dc.subject.mesh Neoadjuvant Therapy
dc.subject.mesh Neovascularization, Pathologic/genetics
dc.subject.mesh Platelet-Derived Growth Factor/metabolism
dc.subject.mesh Receptors, Vascular Endothelial Growth Factor/therapeutic use
dc.subject.mesh Recombinant Fusion Proteins/therapeutic use
dc.subject.mesh Retrospective Studies
dc.subject.mesh Transcriptome/drug effects
dc.subject.mesh Vascular Endothelial Growth Factor A/metabolism/pharmacology
dc.title Angiogenic role of miR-20a in breast cancer
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 29617404
dc.relation.publisherversion https://dx.plos.org/10.1371/journal.pone.0194638
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1371/journal.pone.0194638
dc.journal.title Plos One


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta